Seeking for new therapeutic applications

Scientific Advisors

IRYCISLed by Dr. Victor Manuel Gonzalez, the Group brings the technology of selection and characterization of aptamers developed and implemented by them during the past 12 years. During that time, new methods of aptamers selection and detection systems using aptamers as biorecognition molecule have been developed, and aptamers against different targets have been selected. Through a strategic collaboration agreement, the Group collaborates closely with Aptus Biotech. This collaboration comprehends both R&D projects and aptamer selection services. The Group is also providing new aptamers to be incorporated in the Aptateca (aptamer catalog) with commercial interest.
M. Elena Martín, Ph.D: received her Ph.D. in Biology from the Universidad Autónoma de Madrid (1993). As a predoctoral researcher worked for 3 years in the Hospital Ramón y Cajal. As a postdoctoral, Dr. Martín worked in the Ramon y Cajal and the University of Sussex (UK), School of Biological Sciences. She has been associated professor at the Universidad de Alcalá and in 2000 joined to the Biochemistry Research Service of the Ramon y Cajal Hospital. Since 2002 Dr. Martín actively collaborates with Dr. Víctor M. González in the aptamer field. 
Department of Molecular Evolution at the Centro de Astrobiología (CAB, CSIC-INTA)
CABThe CAB is a research center of the Spanish National Research Council (CSIC), Associated to NASA Astrobiology Institute. Aptus collaborates with Dr. Carlos Briones and Miguel Moreno in the development of AptaVirus applications (HIV and HCV). CAB

Carlos Briones, Ph.D: graduated in Chemistry (Biochemistry and Molecular Biology) at the Universidad Autónoma de Madrid (UAM) in 1992, and received his PhD in Sciences at the same University after completing his thesis at the Centro de Biología Molecular ‘Severo Ochoa’ (CSIC-UAM). Since 2000 he leads his own research group at CAB, focused on the origin and early evolution of life, genetics of RNA viruses, in vitro evolution of nucleic acids (RNA and DNA aptamers), and biosensor development (DNA microarray technology, PNA- and aptamer-based sensors, bionanotechnology-inspired biosensors). He also collaborates in interdisciplinary research projects devoted to the analysis of biodiversity of extreme environments. 
Miguel Moreno Molina, Ph.D: graduated in Molecular and Cell Biology, received his PhD at the la Universidad de Alcalá de Henares. In 2003 he joined to the Dr. Carlos Martínez Group at the Centro Nacional de Biotecnología (CNB, CSIC), where he collaborated with Dr. Laura Lechuga from the Instituto de Microelectrónica de Madrid (CNM-CSIC). As a postdoctoral, from 2006 to 2008 he joined the group of Prof. David Russell Group at the University of East Anglia (Norwich, UK) where he succesfully developed gold nanoparticles with PDT agents and antibodies for anti-cancer treatments. In 2007 co-founded private company Bioapter. Since 2009 he joined Dr. Briones group at the CAB.
UINLocated at the Department of Pharmacology of the Universidad Complutense School of Medicine, is coordinated by Ignacio Lizasoain and María Ángeles Moro and is formed by more than 10 scientists including postdoctoral researchers, PhD students and technicians. The UIN has been created with a dual role, aimed at both research interests and pre (and post) graduate education. As part of academia, a cardinal objective of the unit is the training of future researchers and university professors and lecturers, as well a generation of knowledge. As a research institution, the unit is devoted to the study of the cerebrovascular disease from a basic point of view but also with a strong translational projection, a vocation due to the location in a School of Medicine and developed through a tight partnership with clinical teams. An additional ambition of UIN is the generation of results with industrial interest. 

Since the UIN started in 1998, several results in relation with stroke have been published: J ExpMed, Circulation, J Neurosci, Ann Neurol, FASEB J, Brain Res Rev, Stroke, J CerebBloodFlowMetab, J NeuropatholExpNeurol, J Neurochem, NeurobiolDis, Eur J Neurosci, among others. Quality of theses publications has been demonstrated due to several indices: in January 2013 ISI Web of Knowledge stated that papers from Dra. Moro and Dr. Lizasoain (both with “h”40) have received more than 5.000 cites respectively. Besides, five of their papers received more than 100 cites each one. Both researchers have an impact index over 550.  UIN